European Journal of Heart Failure: Vol 21, No 3

I consent to Wiley Online Library’s Terms of Use and processing of my personal data as disclosed in Wiley’s Privacy Policy.I consent to my personal information being transferred outside of the People’s Republic of China as laid out in Wiley’s Privacy Policy.*(Optional) I consent to special offers, newsletter & promotions from Wiley. See Privacy Policy for more details.

Tools

Submit an article

Journal Metrics

Subscribe to this journal

European Journal of Heart Failure

Journal list menu

Tools

Follow journal

European Journal of Heart Failure: Volume 21, Issue 3

Download PDFs

ISSUE INFORMATION

Issue Information

INTRODUCTION

March 2019 at a glance: epidemiology and clinical trials

HEART FAILURE NEWS

News from the American Heart Association: more on sodium–glucose co-transporter 2 inhibitors, diabetes and heart failure

Medical misinformation: vet the message!

Figures of the Heart Failure Association: Petar M. Seferović, President, 2018–2020

Figures of the Heart Failure Association: Andrew J. Stewart Coats, President-Elect, 2018–2020

HFA POSITION STATEMENT

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

REVIEW

Medication dosing for heart failure with reduced ejection fraction — opportunities and challenges

EPIDEMIOLOGY

Research article

Impact of diabetes and sex in heart failure with reduced ejection fraction patients from the ASIAN-HF registry

Editorial comment

Sex hormones in heart failure revisited?

Research article

Defining a ‘frequent admitter’ phenotype among patients with repeat heart failure admissions

Editorial comment

Applying data science approaches to identify frequent flyers in heart failure: rise of the machines

CLINICAL TRIALS

Research article

Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU

Correction(s) for this article

Corrigendum to ‘Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU’ [Eur J Heart Fail 2019;21:322-333]

Editorial comment

The other serelaxin in acute heart failure study: lessons from a pragmatic clinical trial

Short report

Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial

Editorial comment

Unravelling the effect of sacubitril/valsartan on loop diuretic dosing

Research articles

Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

Long-term outcomes of cardiac resynchronization therapy by left ventricular ejection fraction

Editorial comment

Cardiac resynchronization therapy improves survival in selected patients with moderately impaired ejection fraction — the importance of left ventricular remodelling

Research article

Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy

Editorial comment

Individualizing surgical revascularization in patients with ischaemic heart failure — a further dive into STICHES

RESEARCH LETTERS

Potential role for interleukin-1 in the cardio-renal syndrome

Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline

ERRATUM

Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial. Eur J Heart Fail 2017;19:1179–1185. doi: 10.1002/ejhf.750

This article corrects the following:

Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial

Sign up for email alerts

Tools

More from this journal